Miromatrix Announces CEO Jeff Ross, Ph.D. will Expand His Role by Resuming Leadership of R&D
01 Juin 2023 - 10:01PM
Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company
pioneering a novel technology for bioengineering fully
transplantable organs to help save and improve patients’ lives,
today announced that Miromatrix and John Barry have mutually agreed
to end his employment as Vice President of Research and Development
("R&D") effective on or around June 13, 2023, and that Jeff
Ross, Ph.D., Chief Executive Officer, will assume leadership
responsibilities for the R&D organization.
"This transition does not impact our previously
stated timelines and milestones, and we remain on pace to submit a
response to the Food and Drug Administration’s ("FDA") clinical
hold letter in the second half of 2023 relating to our
miroliverELAPtm IND application," said Jeff Ross, Ph.D., Miromatrix
CEO. "This is a role that I held for several years prior to
becoming CEO and I look forward to working closely again with our
talented team of scientists at this important time in our company’s
history."
About Miromatrix
Miromatrix Medical Inc. is a life sciences
company pioneering a novel technology for bioengineering fully
transplantable human organs to help save and improve patients'
lives. The Company has developed a proprietary perfusion technology
platform for bioengineering organs that it believes will
efficiently scale to address the shortage of available human
organs. The Company's initial development focus is on human livers
and kidneys. For more information, visit miromatrix.com.
Cautionary Statement Regarding
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements other than statements of
historical facts are forward looking statements, including
statements regarding the potential timing of the response to the
FDA’s clinical hold letter relating to the filing of the IND
application for our MiroliverELAP product candidate. In some cases,
you can identify forward-looking statements by terms such as "may,"
"will," "should," "expect," "plan," "anticipate," "could,"
"outlook," "guidance," "intend," "target," "project,"
"contemplate," "believe," "estimate," "predict," "potential,"
"continue," "remain,” or "on pace" or the negative of these terms
or other similar expressions, although not all forward-looking
statements contain these words. The forward-looking statements in
this press release are only predictions and are based largely on
our current business plans, expectations, and projections about
future events and financial trends that we believe may affect our
business, financial condition, and results of operations. These
forward-looking statements speak only as of the date of this press
release and are subject to a number of known and unknown risks,
uncertainties and assumptions, including, but not limited to, our
history of significant losses, which we expect to continue; our
limited history operating as a commercial company; our expectations
with respect to the regulatory pathway of our product candidates,
our ability to obtain regulatory approvals for such product
candidates, and the anticipated effect of delays in obtaining any
such regulatory approvals; our expectations with respect to
preclinical and clinical trial plans for our product candidates,
the results of such activities and the safety and efficacy of our
product candidates; our ability to commercialize our product
candidates; our ability to compete successfully with larger
competitors in our highly competitive industry; our ability to
achieve and maintain adequate levels of coverage or reimbursement
for any future products we may seek to commercialize; our
expectations regarding our manufacturing capabilities; a pandemic,
epidemic or outbreak of an infectious disease in the U.S. or
worldwide, including the outbreak of the novel strain of
coronavirus, COVID-19; product liability claims; our ability to
establish and maintain intellectual property protection for our
products, as well as our ability to operate our business without
infringing the intellectual property rights of others; our ability
to attract and retain senior management and key scientific
personnel; and other important factors that could cause actual
results, performance or achievements to differ materially from
those expected or projected. For information identifying important
factors that could cause actual results to differ materially from
those anticipated in the forward-looking statements, please refer
to the Risk Factors section of the Company's Form 10-K filed with
the U.S. Securities and Exchange Commission and any additional
risks presented in our Quarterly Reports on Form 10-Q and our
Current Reports on Form 8-K. Except as expressly required by
applicable securities law, the Company disclaims any intention or
obligation to update or revise any forward-looking statements
whether as a result of new information, future events or
otherwise.
Investor Contact
Greg Chodaczek
ir@miromatrix.com
Media Contact:
press@miromatrix.com
MiroMatrix Medical (NASDAQ:MIRO)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
MiroMatrix Medical (NASDAQ:MIRO)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024